Coronavirus XBB.1.5 as an Indicator of the Long-Term Continuation of the Covid-19 pandemic. What Next for Vaccination?
https://doi.org/10.31631/2073-3046-2023-22-2-12-22
Abstract
The article discusses the properties of the pandemic strain XBB.1.5 S protein in comparison with the 1918 and 2009 pandemic strains hemagglutinin H1. The S-protein XBB.1.5 already contains more than 40 mutations realized by substituting different amino acids through single and dinucleotide substitutions, deletions and the use of predominantly transversions. The variability of H1N1 influenza virus hemagglutinin is associated with single nucleotide substitutions at a constant length. Conditional extrapolation of influenza virus hemagglutinin variability data on coronavirus S-protein sizes suggests that new pandemic strains will emerge in the next 2-3 years, avoiding the immune defense formed by vaccination against the strains preceding them. The inability to create through the adaptive immune system a long-term immunity to pandemic coronaviruses, as well as to other respiratory viruses with a short incubation cycle, puts on the agenda the need to find new vaccine designs that provide a combination of long-term adaptive and trained immunity. The problem in the search for such vaccines is associated with the regulation of the activity of the innate immune system and ensuring the stability of trained immunity.
About the Author
E. P. Kharchenko
Sechenov Institute of Evolutionary Physiology and Biochemistry
Russian Federation
Russian Federation
Eugene P. Kharchenko – Dr. Sci. (Biol.), leader researcher of I. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy Sciences.
194223, St. Petersburg, Toreza pr., 44. +7 (904) 338-22-80
References
1. Kharchenko EP. The Pandemic is in Progress: Long Covid, Omicrons, Vaccination and Vaccines. Epidemiology and Vaccinal Prevention. 2022; 21(5): 120–137 (In Russ.). doi: 10.31631/2073-3046-2022-21-5-120-137
2. Morens D.M., Taubenberger J.K., Fauci A.S. Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory virusesю. Cell Host & Microbe. 2023 31 146-157. doi:10.1016/j.chom.2022.11.016
3. Kharchenko EP. Novel Method of Immunoepitope Recognition, Long-Term Immunity Markers, Immunosuppressive Domens and Vaccines against COVID-19. Epidemiology and Vaccinal Prevention. 2022;21(1): 4–20 (In Russ.). doi: 10.31631/2073-3046-2022-21-1-4-20
4. https://assets.publishing.service.gov.uk. Can we predict the limits of SARS-CoV-2 variants and their phenotypic consequences?
5. Kharchenko EP. Common Features of Coronavirus and Influenza Pandemics and Surface Proteins of their Pathogens. Parallels. Epidemiology and Vaccinal Prevention. 2021;20(4):4–18 (In Russ.). doi: 10.31631/2073-3046-2021-20-4-4-18
6. Mi-Hyun Lee, Bum-Joon Kim. COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity. Journal of Microbiology.2022; 60(3): 321–334. doi: 10.1007/s12275-022-1621-2
7. Henry C, Palm A-KE, Krammer F., et al. From original antigenic sin to the universal influenza virus vaccine. Trends in immunology. 2018;39(1):70–9. doi: 10.1016/j.it.2017.08.003
8. Souquette A, Thomas PG. Past life and future effects – how heterologous infections alter immunity to influenza viruses. Front. Immunol. 2018;9: article 1071. doi: 10.3389/fimmu.2018.01071
9. Monto A.S., Malosh R.E. , Petrie J.G., Martin E.T. The Doctrine of Original Antigenic Sin: Separating Good From Evil. J Infect Dis.2017; 215(12):1782–1788. doi: 10.1093/infdis/jix173
10. Kharchenko E.P. Occurrence of small homologous and complementary fragments in human virus genomes and their possible role // Russian Journal of Infection and Immunity = Infektsiya i immunitet. 2017; 7 (4): 393–404. (In Russ.). doi: 10.15789/2220-7619-2017-4-393-404.
11. Kharchenko EP. The Occurrence of Genetic Recombination between Viruses and Human – its Possible Influence on Vaccination. Epidemiology and Vaccinal Prevention. 2019;18(5):4 (In Russ.). doi: 10.31631/2073-3046-2019-18-6
12. Taks E. J.M., Moorlag S. J.C.F.M., Netea M.G., van der Meer J. W.M.. Shifting the Immune Memory Paradigm: Trained Immunity in Viral Infections. Annu. Rev. Virol. 2022;9:469– 89. doi: 10.1146/annurev-virology-091919-072546
13. Netea M.G., Domínguez-Andrés J., Barreiro L.B., Chavakis T. Defining trained immunity and its role in health and disease. Nature Reviews Immunology. 2020;20:375–388. doi 10.1038/s41577-020-0285-6
14. Bindu S., Dandapat S., Manikandan R., Dinesh M., et al. Prophylactic and therapeutic insights into trained immunity: A renewed concept of innate immune memory. Human Vaccines & Immunotherapeutics. 2022;18(1):e2040238 (19 pages) doi: 10.1080/21645515.2022.2040238
15. Ochando J., Mulder W. J. M., Madsen J.C., Netea M. G., et al. Trained immunity – basic concepts and contributions to immunopathology. Nature Reviews. Nephrology Reviews. 2023;19:23–37. doi:10.1038/s41581-022-00633-5
16. Edelman G.M . Gaily J.A. Degeneracy and complexity in biological sуstems. Proc. Natl Acad. Sci. USA. 2001;98:13763-13768. doi: 10.1073/pnas.231499798
17. Hoffmann J.A., Kafatos F.C. Janeway C.A., Ezekowitz R.A. Phylogenetic perspectives in innate immunity. Science. 1999; 284: 1313-1318. doi: 10.1126/science.284.5418.1313
18. Crozat K., Vivier E., Dalod M . Crosstalk between components of the innate immune system: promoting anti-microbial defenses and avoiding immunopathologies. Immunological Reviews. 2009; 227:129–149. doi: 10.1111/j.1600-065X.2008.00736.x
19. Kang J.Y., Lee Jie-Oh. Structural biology of the Toll-like receptor family. Annu. Rev. Biochem. 2011;80:917–941. doi: 10.1146/annurev-biochem-052909-141507
20. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34:637–650. doi: 10.1016/j.immuni.2011.05.006
21. Paust S., Senman B., von Andrian U.H. Adaptive immune responses mediated by natural killer cells. Immunological Reviews. 2010;235:286–296. doi: 10.1111/j.01052896.2010.00906.x
22. Mahajan S., Kode V., Bhojak K., Magdalene C.M., et al. Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals. bioRxiv 2020. Preprint. doi:10.1101/2020.11.03.367375
23. Ziogas A., Netea M.G. Trained immunity-related vaccines: innate immune memory and heterologous protection against infections. Trends. Mol Med. 2022;28(6):497–512. doi: 10.1016/j.molmed.2022.03.009
Review
For citations:
Kharchenko E.P. Coronavirus XBB.1.5 as an Indicator of the Long-Term Continuation of the Covid-19 pandemic. What Next for Vaccination? Epidemiology and Vaccinal Prevention. 2023;22(2):12-22. (In Russ.) https://doi.org/10.31631/2073-3046-2023-22-2-12-22
Views:
489
Email this article 